ESMO Virtual Congress 2020
ESMO 2020 Prostate Cancer
- ESMO Virtual Congress 2020: Clinical Factors That Are Prognostic for Survival Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223
- ESMO Virtual Congress 2020: NRG Oncology’s GU007 (NADIR): Niraparib with Standard Combination with ADT and Radiotherapy in High-Risk Prostate Cancer
- ESMO Virtual Congress 2020: DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate (ANZUP 1801)
- ESMO Virtual Congress 2020: Real-World Patterns of Genomic Testing in Patients with Metastatic Castration-Resistant Prostate Cancer
- ESMO Virtual Congress 2020: Quality of Life and Survival in Elderly Metastatic Castration-Resistant Prostate Cancer Patients Treated with Docetaxel
ESMO 2020 Bladder Cancer
- ESMO Virtual Congress 2020: Nivolumab Alone or in Combination with Ipilimumab in Patients with Platinum-Pretreated Metastatic Urothelial Carcinoma: Extended Follow-Up from CheckMate 032
- ESMO Virtual Congress 2020: Molecular Profiling of Post-pembrolizumab Muscle-Invasive Bladder Cancer Reveals Unique Features That May Inspire New Sequential Therapies in Pathological Non-responders
- ESMO Virtual Congress 2020: Real-World Evidence of the Impact of Prior Autoimmune Disease on Immune Checkpoint Inhibitor Outcomes in Patients with Metastatic Urothelial Cancer
- ESMO Virtual Congress 2020: TROPHY-U-01 Cohort 3: Sacituzumab Govitecan and Pembrolizumab in Patients with Progression or Recurrence of Metastatic Urothelial Cancer after Platinum -Based Therapy
- ESMO Virtual Congress 2020: EV-302: Enfortumab Vedotin plus Pembrolizumab and/or Chemotherapy, vs Chemotherapy Alone, in Untreated Locally Advanced or Metastatic Urothelial Cancer
ESMO 2020 Kidney Cancer
- ESMO Virtual Congress 2020: Cabozantinib in Combination with Atezolizumab in Non-Clear Cell Renal Cell Carcinoma: Results from Cohort 10 of the COSMIC-021 Study
- ESMO Virtual Congress 2020: COSMIC-021, Cabozantinib in Combination with Atezolizumab as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma
- ESMO Virtual Congress 2020: Invited Discussant (702O) the COSMIC-021 Trial and (LBA25) the French BIONIKK Trial
- ESMO Virtual Congress 2020: Results From the Phase 2 BIOmarker Driven Trial with Nivolumab and Ipilimumab or VEGFR TKI in Naïve Metastatic Kidney Cancer: the BIONIKK Trial
- ESMO Virtual Congress 2020: Kidney Cancer First-Line Treatment Clinical Trials: Invited Discussant (702O) the COSMIC-021 Trial and (LBA25) the French BIONIKK Trial
ESMO 2020 Testicular and Penile Cancer
- ESMO Virtual Congress 2020: Invited Discussant: Metastatic Penile and Testicular Cancer
- ESMO Virtual Congress 2020: Men with Metastatic Penile Cancer Treated in a Large Quaternary Academic Centre, a Longitudinal Cohort Analysis
- ESMO Virtual Congress 2020: Metachronous Contralateral Testicular Cancer in the Cisplatin Era
- ESMO Virtual Congress 2020: Association Between Human Papillomavirus (HPV) Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma
- ESMO Virtual Congress 2020: Invited Discussant: Penile and Testicular Cancer
ESMO 2020 Press Releases
- ESMO 2020: Two-Pronged Attack Using New Targeted Drug Could Treat ‘Addicted’ Prostate Cancers
- Exelixis Announces Results from Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab
- New First-Line Treatment Option for Metastatic Kidney Cancer, According to Results of Phase 3 Study
- Nivolumab in Combination with Cabozantinib Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial
- BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine